DOCSLIB.ORG

Role of P2y Receptors in the Spinal-Trigeminal System in Vivo and in Vitro

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Role of P2y Receptors in the Spinal-Trigeminal System in Vivo and in Vitro UNIVERSITÀ DEGLI STUDI DI MILANO Facoltà di Farmacia Dipartimento di Scienze Farmacologiche Corso di Dottorato di Ricerca in Scienze Farmacotossicologiche, Farmacognostiche e Biotecnologie Farmacologiche (XXIII CICLO) Graduate School in Pharmacological Sciences / Scuola di Dottorato in Scienze farmacologiche TESI DI DOTTORATO DI RICERCA PURINERGIC TRANSMISSION IN MIGRAINE: ROLE OF P2Y RECEPTORS IN THE SPINAL-TRIGEMINAL SYSTEM IN VIVO AND IN VITRO BIO/14 Tesi di dottorato di: GIOVANNI VILLA MATRICOLA: R07517 TUTOR: Chiar.ma Prof.ssa Maria Pia ABBRACCHIO CORRELATORE: Dr.ssa Stefania CERUTI COORDINATORE: Chiar.mo Prof. Guido FRANCESCHINI ANNO ACCADEMICO 2009/2010 Index INDEX 1. INTRODUCTION _______________________________ 1 1.1 PAIN AND NOCICEPTION 2 1.1.1 Molecular basis of nociception 3 1.1.2 The trigeminal nerve and the spinal-trigeminal system 4 1.1.3 Role of non-neuronal cells in pain transmission 9 1.2 MIGRAINE 12 1.2.1 Description of the migraine attack 14 1.2.2 How and where does the migraine attack originate? 15 1.2.3 Familial hemiplegic migraine 21 1.2.4 Current and future pharmacological treatment of migraine 24 1.3 THE PURINERGIC SYSTEM 29 1.3.1 Purinergic signalling 30 1.3.2 P2X receptors 32 1.3.3 P2Y receptors 33 1.3.4 Pathophysiological roles of extracellular nucleotides in the nervous system 36 1.4 PURINES AND PAIN 41 1.4.1 Role of P2X receptors in pain transmission 42 1.4.2 Role of P2Y receptors in pain transmission: sensory ganglia 46 1.4.3 Role of P2Y receptors in pain transmission: CNS 48 2. AIM OF THE STUDY ____________________________ 51 3. METHODS ____________________________________ 55 3.1 CELL CULTURES 56 3.2 PHARMACOLOGICAL TREATMENTS 58 3.3 IMMUNOCYTOCHEMISTRY 58 3.4 IMMUNOCYTOCHEMISTRY 59 Index 3.4.1 Tissue processing 59 3.4.2 Immunostaining of tissues 59 3.4.3 Quantification of results and data analysis 60 3.5 INTRACELLULAR CALCIUM MEASUREMENTS 61 3.6 TOTAL RNA ISOLATION AND RT-PCR ANALYSIS 62 3.7 WESTERN-BLOTTING ANALYSIS 65 3.8 ANALYSIS OF CGRP RELEASE BY ENZYME IMMUNO-ASSAY (EIA) 65 3.9 IN VIVO EXPERIMENTS 66 3.9.1 Animals 66 3.9.2 Orofacial formalin test 66 3.9.3 Synthesis of dsRNAs and their injection into the trigeminal ganglion 67 3.9.4 Induction of TMJ inflammation 67 3.9.5 Behavioral tests 68 3.9.6 Measurement of Evans’ blue dye extravasation 68 3.10 STATISTICAL ANALYSIS 69 4. RESULTS - Section I: in vitro studies ________________ 70 4.1 SET UP OF PRIMARY MIXED TRIGEMINAL CULTURES AS AN IN VITRO MODEL FOR STUDYING CELL TO CELL COMMUNICATION IN THE TRIGEMINAL GANGLIA 71 4.2 BOTH TRIGEMINAL NEURONS AND SATELLITE GLIAL CELLS BEAR FUNCTIONAL P2 RECEPTORS 74 4.3.. CHRONIC APPLICATION OF THE PRO-INFLAMMATORY MEDIATOR BRADYKININ DIFFERENTIALLY AFFECTS NEURONAL P2X3 AND GLIAL P2Y RECEPTOR FUNCTIONALITY 79 4.4 FOLLOWING BK APPLICATION, CGRP RELEASED FROM TG NEURONS IS RESPONSIBLE FOR P2Y RECEPTORS UPREGULATION IN SGCs 82 4.5 CGRP, BUT NOT BK, RETAINS ITS ABILITY TO INDUCE P2Y RECEPTOR POTENTIATION IN PURIFIED SGCs CULTURES 84 4.6.. THE ERK1/2 MAP KINASE PATHWAY HAS A PRIMARY ROLE IN CGRP- INDUCED POTENTIATION OF GLIAL P2Y RECEPTORS 86 4.7 CGRP RELEASE IS SIGNIFICANTLY ENHANCED IN TG CULTURES FROM CaV2.1 α1 R192Q MUTANT KNOCK-IN MICE 87 4.8.. APPLICATION OF BK INCREASES THE NUMBER OF ADP- AND UTP- RESPONDING SGCs IN TG CULTURES FROM CaV2.1 R192Q KI MICE 88 Index 4. RESULTS - Section I: in vivo studies ________________ 91 4.9 SET UP OF IN VIVO MODELS OF TRIGEMINAL PAIN FOR STUDYING ROLE OF THE PURINERGIC SYSTEM IN PAIN TRANSMISSION 92 4.10 SGCs AND MACROPHAGES ARE SELECTIVELY ACTIVATED IN TG FOLLOWING TMJ INFLAMMATION 95 4.11.. MICROGLIAL CELLS, BUT NOT ASTROCYTES, ARE ACTIVATED IN THE SPINAL TRIGEMINAL NUCLEUS FOLLOWING TMJ INFLAMMATION 98 4.12 THE PURINERGIC P2Y12 RECEPTOR IS SELECTIVELY EXPRESSED BY MICROGLIAL CELLS IN THE CNS, BUT IT IS NOT UPREGULATED BY TMJ INFLAMMATION 101 5. DISCUSSION __________________________________ 103 5.1 PRIMARY MIXED TG CULTURES AS AN IN VITRO MODEL FOR EVALUATING P2 RECEPTOR EXPRESSION AND FUNCTIONALITY 104 5.2 EXPOSURE TO ALGOGENS EXERT A COMPLEX MODULATION OF P2 RECEPTOR FUNCTIONALITY IN NEURONS AND GLIAL CELLS 107 5.3.. THE GAIN-OF-FUNCTION MUTATION IN CaV2.1 CALCIUM CHANNELS AFFECTS P2Y RECEPTORS FUNCTIONALITY IN SGCs 108 5.4.. SET UP OF IN VIVO MODELS OF TRIGEMINAL PAIN AS TOOLS FOR EVALUATING THE ROLE OF GLIAL P2Y RECEPTORS IN PAIN TRANSMISSION 110 6. REFERENCES _________________________________ 115 7. ABBREVIATIONS ______________________________ 132 1. INTRODUCTION Introduction 1.1 PAIN AND NOCICEPTION Pain can be defined as “an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage” (Merskey & Bogduk, 1994). It is a physical sensation arising from parts of the body, but it is also always unpleasant and therefore become an emotional experience. Experiences which resemble pain but are not unpleasant, e.g., pricking, should not be called pain (Merskey & Bogduk, 1994). Pain is a submodality of somatic sensation like touch and pressure, and serves as an important protective function by warning of injury that should be avoided or treated. However, unlike other somatic submodalities, and unlike vision, hearing, and smell, pain has an urgent and primitive quality, which is responsible for the affective and emotional aspects of pain perception (Basbaum & Jessell, 2000). The concept of pain is further complicated by the fact that its perception is always subjective. In fact, under similar conditions the same stimulus can produce different responses in different individuals (Merskey & Bogduk, 1994). Moreover, many people report pain in the absence of tissue damage or any likely pathophysiological cause; usually this happens for psychological reasons. The highly individual and subjective nature of pain makes difficult to treat it clinically. There are no “painful stimuli” that invariably elicit the perception of pain in all individuals. For example, many wounded soldiers do not feel pain until they are safely removed from battle. Similarly, athletes often do not detect their injuries until their game is over (Basbaum & Jessell, 2000). Pain can be subdivided in physiological pain and pathological or clinical pain. Physiological pain (also called acute pain, sometimes referred to as ‘‘good’’ pain) is adaptive, transient, and has a protective role that warns of potential tissue damage in response to a noxious stimulus. Pathological pain, or clinical pain (also called chronic, ‘‘bad’’ pain) is usually maladaptive, persistent, and serves no meaningful defensive, or other helpful purpose (Cao & Zhang, 2008). This kind of pain is mainly subdivided into neuropathic pain, i.e. pain associated with damage or dysfunction of the peripheral nervous system (PNS) and central nervous system (CNS), and inflammatory pain, i.e. pain related to peripheral tissue damage/inflammation (e.g. arthritic pain). In addition, other types of pathological pain, such as cancer pain, and pain elicited by continuous infusion of morphine, share some features with inflammatory and neuropathic pain but also have their distinct characteristics (Brennan et al., 1996; Mantyh et al., 2002). 2 Introduction Pathological pain is typically characterized by hyperalgesia (increased responsiveness to noxious stimuli) and allodynia (painful responses to normally innocuous stimuli), as well as by spontaneous pain. Pain hypersensitivity is not only produced in the injured tissue or territory (innervated by the injured nerve), but also spread to the adjacent non- injured regions or the extraterritory (extraterritorial pain) and to the contralateral body (mirror-image pain). This exaggerated pain is thought to result from peripheral sensitization (increase in sensitivity of nociceptive primary afferent neurons) and central sensitization (hyperexcitability of nociceptive neurons in the CNS (Cao & Zhang, 2008). In the following paragraphs the basic principles of nociception, as well as the nociceptive neuronal pathways associated to the trigeminal perception of pain, will be discussed. Finally, the emerging role(s) of CNS and PNS glial cells in pain genesis and maintenance will be analyzed. 1.1.1 Molecular basis of nociception Nociception is the process by which intense thermal, mechanical, or chemical stimuli are detected by a subpopulation of peripheral nerve fibers, called nociceptors (Basbaum et al., 2009). The cell bodies of nociceptors are located in the dorsal root ganglia (DRG) for the body, and the trigeminal ganglia (TG) for the head district, and have both a peripheral and central axonal branch that innervates their target organ and the spinal cord/brainstem, respectively (Lazarov, 2002). There are two major classes of nociceptors (Meyer at al., 2008). The first includes medium diameter myelinated (Aδ) afferents that mediate acute, well-localized “first” or fast pain (conducting signals at about 5-30 m/s). These myelinated afferents differ considerably from the larger diameter and rapidly conducting Aβ fibers that respond to innocuous mechanical stimulation (i.e., light touch). The second class of nociceptor includes small diameter unmyelinated “C” fibers that convey poorly localized, “second” or slow pain (conducting signals at a rate of less than 1.0 m/s). Neuroanatomical and molecular characterization of nociceptors has further demonstrated their heterogeneity, particularly for the C fibers (Basbaum et al., 2009). For example, the so-called “peptidergic” population of C nociceptors releases neuropeptides, substance P (SP), and calcitonin-gene related peptide (CGRP); they also 3 Introduction express the TrkA neurotrophin receptor, which responds to nerve growth factor (NGF). The nonpeptidergic population of C nociceptors expresses the c-Ret neurotrophin receptor that is targeted by glial-derived neurotrophic factor (GDNF), and a large percentage of the c-Ret-positive population also binds the IB4 isolectin and expresses the specific purinergic P2X3 receptor subtypes (see also Paragraph 1.4.3, Ruan & Burnstock, 2003; Basbaum et al., 2009).
Load more

Recommended publications
  • Cangrelor Ameliorates CLP-Induced Pulmonary Injury in Sepsis By
    Luo et al. Eur J Med Res (2021) 26:70 https://doi.org/10.1186/s40001-021-00536-4 European Journal of Medical Research RESEARCH Open Access Cangrelor ameliorates CLP-induced pulmonary injury in sepsis by inhibiting GPR17 Qiancheng Luo1†, Rui Liu2†, Kaili Qu3, Guorong Liu1, Min Hang1, Guo Chen1, Lei Xu1, Qinqin Jin1 , Dongfeng Guo1* and Qi Kang1* Abstract Background: Sepsis is a common complication of severe wound injury and infection, with a very high mortality rate. The P2Y12 receptor inhibitor, cangrelor, is an antagonist anti-platelet drug. Methods: In our study, we investigated the protective mechanisms of cangrelor in CLP-induced pulmonary injury in sepsis, using C57BL/6 mouse models. Results: TdT-mediated dUTP Nick-End Labeling (TUNEL) and Masson staining showed that apoptosis and fbrosis in lungs were alleviated by cangrelor treatment. Cangrelor signifcantly promoted surface expression of CD40L on platelets and inhibited CLP-induced neutrophils in Bronchoalveolar lavage fuid (BALF) (p < 0.001). We also found that cangrelor decreased the infammatory response in the CLP mouse model and inhibited the expression of infamma- tory cytokines, IL-1β (p < 0.01), IL-6 (p < 0.05), and TNF-α (p < 0.001). Western blotting and RT-PCR showed that cangre- lor inhibited the increased levels of G-protein-coupled receptor 17 (GPR17) induced by CLP (p < 0.001). Conclusion: Our study indicated that cangrelor repressed the levels of GPR17, followed by a decrease in the infam- matory response and a rise of neutrophils in BALF, potentially reversing CLP-mediated pulmonary injury during sepsis. Keywords: Sepsis, Infammation, Cangrelor, Platelet, GPR17 Background Te lung is one of the initial target organ of the systemic Sepsis is a serious disease and will lead a high mortal- infammatory response caused by sepsis, leading to alve- ity rate of approximately 22% in all over the world [1].
    [Show full text]
  • Kengrexal, INN-Cangrelor Tetrasodium
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Kengrexal 50 mg powder for concentrate for solution for injection/infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains cangrelor tetrasodium corresponding to 50 mg cangrelor. After reconstitution 1 mL of concentrate contains 10 mg cangrelor. After dilution 1 mL of solution contains 200 micrograms cangrelor. Excipient with known effect Each vial contains 52.2 mg sorbitol. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Powder for concentrate for solution for injection/infusion. White to off-white lyophilised powder. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Kengrexal, co-administered with acetylsalicylic acid (ASA), is indicated for the reduction of thrombotic cardiovascular events in adult patients with coronary artery disease undergoing percutaneous coronary intervention (PCI) who have not received an oral P2Y12 inhibitor prior to the PCI procedure and in whom oral therapy with P2Y12 inhibitors is not feasible or desirable. 4.2 Posology and method of administration Kengrexal should be administered by a physician experienced in either acute coronary care or in coronary intervention procedures and is intended for specialised use in an acute and hospital setting. Posology The recommended dose of Kengrexal for patients undergoing PCI is a 30 micrograms/kg intravenous bolus followed immediately by 4 micrograms/kg/min intravenous infusion. The bolus and infusion should be initiated prior to the procedure and continued for at least two hours or for the duration of the procedure, whichever is longer. At the discretion of the physician, the infusion may be continued for a total duration of four hours, see section 5.1.
    [Show full text]
  • P2 Receptors in Cardiovascular Regulation and Disease
    Purinergic Signalling (2008) 4:1–20 DOI 10.1007/s11302-007-9078-7 REVIEW P2 receptors in cardiovascular regulation and disease David Erlinge & Geoffrey Burnstock Received: 3 May 2007 /Accepted: 22 August 2007 /Published online: 21 September 2007 # Springer Science + Business Media B.V. 2007 Abstract The role of ATP as an extracellular signalling Introduction molecule is now well established and evidence is accumulating that ATP and other nucleotides (ADP, UTP and UDP) play Ever since the first proposition of cell surface receptors for important roles in cardiovascular physiology and pathophysi- nucleotides [1, 2], it has become increasingly clear that, in ology, acting via P2X (ion channel) and P2Y (G protein- addition to functioning as an intracellular energy source, the coupled) receptors. In this article we consider the dual role of purines and pyrimidines ATP, adenosine diphosphate ATP in regulation of vascular tone, released as a cotransmitter (ADP), uridine triphosphate (UTP) and uridine diphosphate from sympathetic nerves or released in the vascular lumen in (UDP) can serve as important extracellular signalling response to changes in blood flow and hypoxia. Further, molecules [3, 4] acting on 13 P2X homo- and heteromul- purinergic long-term trophic and inflammatory signalling is timer ionotropic and 8 P2Y metabotropic receptor subtypes described in cell proliferation, differentiation, migration and [5, 6] (Table 1). To terminate signalling, ectonucleotidases death in angiogenesis, vascular remodelling, restenosis and are present in the circulation and on cell surfaces, rapidly atherosclerosis. The effects on haemostasis and cardiac degrading extracellular ATP into ADP, AMP and adenosine regulation is reviewed. The involvement of ATP in vascular [7, 8].
    [Show full text]
  • A Comparative Study of Molecular Structure, Pka, Lipophilicity, Solubility, Absorption and Polar Surface Area of Some Antiplatelet Drugs
    International Journal of Molecular Sciences Article A Comparative Study of Molecular Structure, pKa, Lipophilicity, Solubility, Absorption and Polar Surface Area of Some Antiplatelet Drugs Milan Remko 1,*, Anna Remková 2 and Ria Broer 3 1 Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Comenius University in Bratislava, Odbojarov 10, SK-832 32 Bratislava, Slovakia 2 Department of Internal Medicine, Faculty of Medicine, Slovak Medical University, Limbová 12, SK–833 03 Bratislava, Slovakia; [email protected] 3 Department of Theoretical Chemistry, Zernike Institute for Advanced Materials, University of Groningen, Nijenborgh 4, 9747 AG Groningen, The Netherlands; [email protected] * Correspondence: [email protected]; Tel.: +421-2-5011-7291 Academic Editor: Michael Henein Received: 18 February 2016; Accepted: 11 March 2016; Published: 19 March 2016 Abstract: Theoretical chemistry methods have been used to study the molecular properties of antiplatelet agents (ticlopidine, clopidogrel, prasugrel, elinogrel, ticagrelor and cangrelor) and several thiol-containing active metabolites. The geometries and energies of most stable conformers of these drugs have been computed at the Becke3LYP/6-311++G(d,p) level of density functional theory. Computed dissociation constants show that the active metabolites of prodrugs (ticlopidine, clopidogrel and prasugrel) and drugs elinogrel and cangrelor are completely ionized at pH 7.4. Both ticagrelor and its active metabolite are present at pH = 7.4 in neutral undissociated form. The thienopyridine prodrugs ticlopidine, clopidogrel and prasugrel are lipophilic and insoluble in water. Their lipophilicity is very high (about 2.5–3.5 logP values). The polar surface area, with regard to the structurally-heterogeneous character of these antiplatelet drugs, is from very large interval of values of 3–255 Å2.
    [Show full text]
  • Lecture 12 Notes
    Somatic regions Limbic regions These functionally distinct regions continue rostrally into the ‘tweenbrain. Fig 11-4 Courtesy of MIT Press. Used with permission. Schneider, G. E. Brain structure and its Origins: In the Development and in Evolution of Behavior and the Mind. MIT Press, 2014. ISBN: 9780262026734. 1 Chapter 11, questions about the somatic regions: 4) There are motor neurons located in the midbrain. What movements do those motor neurons control? (These direct outputs of the midbrain are not a subject of much discussion in the chapter.) 5) At the base of the midbrain (ventral side) one finds a fiber bundle that shows great differences in relative size in different species. Give examples. What are the fibers called and where do they originate? 8) A decussating group of axons called the brachium conjunctivum also varies greatly in size in different species. It is largest in species with the largest neocortex but does not come from the neocortex. From which structure does it come? Where does it terminate? (Try to guess before you look it up.) 2 Motor neurons of the midbrain that control somatic muscles: the oculomotor nuclei of cranial nerves III and IV. At this level, the oculomotor nucleus of nerve III is present. Fibers from retina to Superior Colliculus Brachium of Inferior Colliculus (auditory pathway to thalamus, also to SC) Oculomotor nucleus Spinothalamic tract (somatosensory; some fibers terminate in SC) Medial lemniscus Cerebral peduncle: contains Red corticospinal + corticopontine fibers, + cortex to hindbrain fibers nucleus (n. ruber) Tectospinal tract Rubrospinal tract Courtesy of MIT Press. Used with permission. Schneider, G.
    [Show full text]
  • Expression of Dual Nucleotidescysteinylleukotrienes
    J. Cell. Mol. Med. Vol 18, No 9, 2014 pp. 1785-1796 Expression of dual Nucleotides/Cysteinyl-Leukotrienes Receptor GPR17 in early trafficking of cardiac stromal cells after myocardial infarction Simona Cosentino a, #, Laura Castiglioni b, #, Francesca Colazzo a, #, Elena Nobili a, Elena Tremoli b, Patrizia Rosa c, Maria P. Abbracchio b, #, Luigi Sironi b, #, Maurizio Pesce d, #, * a Laboratorio di Biologia e Biochimica dell’Aterotrombosi, Centro Cardiologico Monzino, IRCCS, Milan, Italy b Dipartimento di Scienze Farmacologiche e Biomolecolari, Universita di Milano, Milan, Italy c Dipartimento di Biotecnologie Mediche e Medicina Traslazionale (BIOMETRA), Istituto di Neuroscienze, Milan, Italy d Laboratorio di Ingegneria Tissutale Cardiovascolare, Centro Cardiologico Monzino, IRCCS, Milan, Italy Received: November 8, 2013; Accepted: March 25, 2014 Abstract GPR17 is a Gi-coupled dual receptor activated by uracil-nucleotides and cysteinyl-leukotrienes. These mediators are massively released into hypoxic tissues. In the normal heart, GPR17 expression has been reported. By contrast, its role in myocardial ischaemia has not yet been assessed. In the present report, the expression of GPR17 was investigated in mice before and at early stages after myocardial infarction by using immunofluorescence, flow cytometry and RT-PCR. Before induction of ischaemia, results indicated the presence of the receptor in a pop- ulation of stromal cells expressing the stem-cell antigen-1 (Sca-1). At early stages after ligation of the coronary artery, the receptor was expressed in Sca-1+ cells, and cells stained with Isolectin-B4 and anti-CD45 antibody. GPR17+ cells also expressed mesenchymal marker CD44. GPR17 function was investigated in vitro in a Sca-1+/CD31À cell line derived from normal hearts.
    [Show full text]
  • Brainstem and Its Associated Cranial Nerves
    Brainstem and its Associated Cranial Nerves Anatomical and Physiological Review By Sara Alenezy With appreciation to Noura AlTawil’s significant efforts Midbrain (Mesencephalon) External Anatomy of Midbrain 1. Crus Cerebri (Also known as Basis Pedunculi or Cerebral Peduncles): Large column of descending ​ “Upper Motor Neuron” fibers that is responsible for movement coordination, which are: a. Frontopontine fibers b. Corticospinal fibers Ventral Surface c. Corticobulbar fibers d. Temporo-pontine fibers 2. Interpeduncular Fossa: Separates the Crus Cerebri from the middle. ​ 3. Nerve: 3rd Cranial Nerve (Oculomotor) emerges from the Interpeduncular fossa. ​ 1. Superior Colliculus: Involved with visual reflexes. ​ ​ ​ ​ Dorsal Surface 2. Inferior Colliculus: Involved with auditory reflexes. ​ ​ ​ 3. Nerve: 4th Cranial Nerve (Trochlear) emerges caudally to the Inferior Colliculus after decussating in the ​ superior medullary velum. Internal Anatomy of Midbrain 1. Superior Colliculus: Nucleus of grey matter that is associated with the Tectospinal Tract (descending) and the Spinotectal Tract ​ (ascending). a. Tectospinal Pathway: turning the head, neck and eyeballs in response to a visual stimuli.1 Level of ​ ​ ​ b. Spinotectal Pathway: turning the head, neck and eyeballs in response to a cutaneous stimuli.2 Superior ​ ​ ​ ​ 2. Oculomotor Nucleus: Situated in the periaqueductal grey matter. Colliculus ​ 3. Red Nucleus: Red mass3 of grey matter situated centrally in the Tegmentum. Involved in motor control (Rubrospinal Tract). ​ 1. Inferior Colliculus: Nucleus of grey matter that is associated with the Tectospinal Tract (descending) and the Spinotectal Tract ​ (ascending). Tectospinal Pathway: turning the head, neck and eyeballs in response to a auditory stimuli. ​ ​ ​ ​ 2. Trochlear Nucleus: Situated in the periaqueductal grey matter. Level of ​ Inferior 3.
    [Show full text]
  • Practical Guidance for the Evaluation and Management of Drug Hypersensitivity: Specific Drugs
    Specific Drugs Practical Guidance for the Evaluation and Management of Drug Hypersensitivity: Specific Drugs Chief Editors: Ana Dioun Broyles, MD, Aleena Banerji, MD, and Mariana Castells, MD, PhD Ana Dioun Broyles, MDa, Aleena Banerji, MDb, Sara Barmettler, MDc, Catherine M. Biggs, MDd, Kimberly Blumenthal, MDe, Patrick J. Brennan, MD, PhDf, Rebecca G. Breslow, MDg, Knut Brockow, MDh, Kathleen M. Buchheit, MDi, Katherine N. Cahill, MDj, Josefina Cernadas, MD, iPhDk, Anca Mirela Chiriac, MDl, Elena Crestani, MD, MSm, Pascal Demoly, MD, PhDn, Pascale Dewachter, MD, PhDo, Meredith Dilley, MDp, Jocelyn R. Farmer, MD, PhDq, Dinah Foer, MDr, Ari J. Fried, MDs, Sarah L. Garon, MDt, Matthew P. Giannetti, MDu, David L. Hepner, MD, MPHv, David I. Hong, MDw, Joyce T. Hsu, MDx, Parul H. Kothari, MDy, Timothy Kyin, MDz, Timothy Lax, MDaa, Min Jung Lee, MDbb, Kathleen Lee-Sarwar, MD, MScc, Anne Liu, MDdd, Stephanie Logsdon, MDee, Margee Louisias, MD, MPHff, Andrew MacGinnitie, MD, PhDgg, Michelle Maciag, MDhh, Samantha Minnicozzi, MDii, Allison E. Norton, MDjj, Iris M. Otani, MDkk, Miguel Park, MDll, Sarita Patil, MDmm, Elizabeth J. Phillips, MDnn, Matthieu Picard, MDoo, Craig D. Platt, MD, PhDpp, Rima Rachid, MDqq, Tito Rodriguez, MDrr, Antonino Romano, MDss, Cosby A. Stone, Jr., MD, MPHtt, Maria Jose Torres, MD, PhDuu, Miriam Verdú,MDvv, Alberta L. Wang, MDww, Paige Wickner, MDxx, Anna R. Wolfson, MDyy, Johnson T. Wong, MDzz, Christina Yee, MD, PhDaaa, Joseph Zhou, MD, PhDbbb, and Mariana Castells, MD, PhDccc Boston, Mass; Vancouver and Montreal,
    [Show full text]
  • The Human Cortical Dental Pain Matrix : Neural Activation Patterns of Tooth Pain Investigated with Fmri
    Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2011 The human cortical dental pain matrix : neural activation patterns of tooth pain investigated with fMRI Brügger, Michael Posted at the Zurich Open Repository and Archive, University of Zurich ZORA URL: https://doi.org/10.5167/uzh-164035 Dissertation Published Version Originally published at: Brügger, Michael. The human cortical dental pain matrix : neural activation patterns of tooth pain investigated with fMRI. 2011, University of Zurich, Faculty of Arts. The Human Cortical Dental Pain Matrix Neural Activation Patterns of Tooth Pain investigated with fMRI Thesis presented to the Faculty of Arts of the University of Zurich for the degree of Doctor of Philosophy by Michael Brügger of Marbach SG Accepted in the spring semester 2009 on the recommendation of Prof. Dr. rer. nat. Lutz Jäncke and Prof. Dr. med. dent. Sandro Palla Zurich, 2011 …the authors "art‐like" interpretation of a human brain under tooth pain… CONTENTS SUMMARY .................................................................................................................................. 6 ZUSAMMENFASSUNG ................................................................................................................ 7 PREFACE ..................................................................................................................................... 9 1. INTRODUCTION ....................................................................................................
    [Show full text]
  • A. Diencephalon B. Telencephalon C. Metencephalon D
    SAMPLE TEST QUESTIONS Select the one best answer. l. The olfactory nerve is attached to the: A. Diencephalon B. Telencephalon C. Metencephalon D. Mesencephalon E. Myelencephalon 2. Following complete transection of a peripheral nerve, all the following may occur except: A. Chromatoloysis in the cell body. B. Degeneration of peripheral myelin distal to the site of injury. C. Degeneration of the axon distal to the site of injury. D. Immediate restoration of normal function following prompt surgical repair. E. Outgrowth of axonal sprouting from the proximal nerve stump .. 3. A lesion of the left hypoglossal nerve causes: A. Loss of taste sensation on the left side of the tongue. B. Deviation of the tongue to the right side, upon protrusion. C. Total inability to protrude the tongue. D. Deviation of the tongue to the left, upon protrusion. E. Hoarseness. 4. In the brain stem, the principle sensory decussation f0r general sensation ca~ried in the posterior columns of the spinal cord forms the: A. Medial lemniscus. B. Lateral lemniscus. C. Central tegmental fasciculus D. Medial longitudinal fasciculus E. Spinal lemniscus. 5. All are true of the lateral spinothalamic tract except: A. It caries sensations of pain and thermal sense. B. Fibers from sacral origin are located in the ventro-medial portion of the tract. C. Decussation occurs within one or two spinal segments of its origin. D. Fibers of cervical origin are located in the ventro-medial portion of the tract. E. It forms part of the brain stem lemniscal systems. 81 6. A unilateral lesion of the internal capsule involving the genu and the posterior limb, would cause: A.
    [Show full text]
  • Advances in Interventional Cardiology New Directions In
    Advances in Interventional Cardiology New Directions in Antiplatelet Therapy Jose´ Luis Ferreiro, MD; Dominick J. Angiolillo, MD, PhD therosclerosis is a chronic inflammatory process that is A2 (TXA2) from arachidonic acid through selective acetylation Aknown to be the underlying cause of coronary artery of a serine residue at position 529 (Ser529). TXA2 causes disease (CAD).1 In addition to being the first step of primary changes in platelet shape and enhances recruitment and aggre- hemostasis, platelets play a pivotal role in the thrombotic gation of platelets through its binding to thromboxane and process that follows rupture, fissure, or erosion of an athero- prostaglandin endoperoxide (TP) receptors. Therefore, aspirin sclerotic plaque.2 Because atherothrombotic events are essen- decreases platelet activation and aggregation processes mediated tially platelet-driven processes, this underscores the impor- by TP receptor pathways.7 tance of antiplatelet agents, which represent the cornerstone Although the optimal dose of aspirin has been the subject of treatment, particularly in the settings of patients with acute of debate, the efficacy of low-dose aspirin is supported by the coronary syndromes (ACS) and undergoing percutaneous results of numerous studies.8–10 In these investigations, a coronary intervention (PCI). dose-dependent risk for bleeding, particularly upper gastro- Currently, there are 3 different classes of antiplatelet drugs that are approved for clinical use and recommended per intestinal bleeding, with no increase in
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2011) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2011) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]